In conclusion, in our proof-of-concept study, we found that MEP and lactoferrin, when administered three months after initial infection in patients with a new diagnosis of long covid, may have a positive impact on improving Long COVID symptoms in children during follow-up evaluations. Here, LTF is linked to infection.